KR102762199B1 - 만성 폐쇄성 폐 질환의 급성 악화 치료를 위한 투약법 - Google Patents

만성 폐쇄성 폐 질환의 급성 악화 치료를 위한 투약법 Download PDF

Info

Publication number
KR102762199B1
KR102762199B1 KR1020247020223A KR20247020223A KR102762199B1 KR 102762199 B1 KR102762199 B1 KR 102762199B1 KR 1020247020223 A KR1020247020223 A KR 1020247020223A KR 20247020223 A KR20247020223 A KR 20247020223A KR 102762199 B1 KR102762199 B1 KR 102762199B1
Authority
KR
South Korea
Prior art keywords
cyanobenzoyl
methylbenzamide
pyrazol
cyclopropyl
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020247020223A
Other languages
English (en)
Korean (ko)
Other versions
KR20240101698A (ko
Inventor
콜린 오포드
시릴 클라크
콜름 패럴
재클린 파킨
스테판 드 벅
Original Assignee
메레오 바이오파마 1 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메레오 바이오파마 1 리미티드 filed Critical 메레오 바이오파마 1 리미티드
Publication of KR20240101698A publication Critical patent/KR20240101698A/ko
Application granted granted Critical
Publication of KR102762199B1 publication Critical patent/KR102762199B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020247020223A 2016-03-08 2016-03-08 만성 폐쇄성 폐 질환의 급성 악화 치료를 위한 투약법 Active KR102762199B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/GB2016/050636 WO2017153702A1 (en) 2016-03-08 2016-03-08 Dosage regimen for the treatment of acute exacerbations of chronic obstructive pulmonary disease
KR1020187026084A KR20180118667A (ko) 2016-03-08 2016-03-08 만성 폐쇄성 폐 질환의 급성 악화 치료를 위한 투약법

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020187026084A Division KR20180118667A (ko) 2016-03-08 2016-03-08 만성 폐쇄성 폐 질환의 급성 악화 치료를 위한 투약법

Publications (2)

Publication Number Publication Date
KR20240101698A KR20240101698A (ko) 2024-07-02
KR102762199B1 true KR102762199B1 (ko) 2025-02-07

Family

ID=55586330

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020247020223A Active KR102762199B1 (ko) 2016-03-08 2016-03-08 만성 폐쇄성 폐 질환의 급성 악화 치료를 위한 투약법
KR1020187026084A Ceased KR20180118667A (ko) 2016-03-08 2016-03-08 만성 폐쇄성 폐 질환의 급성 악화 치료를 위한 투약법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020187026084A Ceased KR20180118667A (ko) 2016-03-08 2016-03-08 만성 폐쇄성 폐 질환의 급성 악화 치료를 위한 투약법

Country Status (9)

Country Link
US (2) US10603306B2 (https=)
JP (1) JP6741774B2 (https=)
KR (2) KR102762199B1 (https=)
AU (1) AU2016397047B2 (https=)
BR (1) BR112018067454A2 (https=)
CA (1) CA3016488C (https=)
MX (1) MX385717B (https=)
RU (1) RU2713203C1 (https=)
WO (1) WO2017153702A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102762199B1 (ko) * 2016-03-08 2025-02-07 메레오 바이오파마 1 리미티드 만성 폐쇄성 폐 질환의 급성 악화 치료를 위한 투약법
GB201612238D0 (en) 2016-07-14 2016-08-31 Mereo Biopharma 1 Ltd Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-Yl]-n-cyclopropyl-4-methylbenzamide
GB201612240D0 (en) 2016-07-14 2016-08-31 Mereo Biopharma 1 Ltd Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide
JP7280627B2 (ja) * 2017-12-11 2023-05-24 メレオ バイオファーマ １ リミテッド 慢性閉塞性肺疾患の急性増悪の処置における３－［５－アミノ－４－（３－シアノベンゾイル）－ピラゾール－１－イル］－ｎ－シクロプロピル－４－メチルベンズアミドの使用
AU2018381874B2 (en) 2017-12-11 2024-08-15 Mereo Biopharma 1 Limited Use of 3-(5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl)-N-cyclopropyl-4-methylbenzamide in the prevention or reduction of acute exacerbations of chronic obstructive pulmonary disease

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030192533A1 (en) 1997-12-31 2003-10-16 Astra Aktiebolag, A Sweden Corporation New method
WO2005009973A1 (en) 2003-06-26 2005-02-03 Novartis Ag 5-membered heterocycle-based p38 kinase inhibitors
WO2005110452A2 (en) 2004-04-09 2005-11-24 Abbott Biotechnology Ltd. MULTIPLE-VARIABLE DOSE REGIMEN FOR TREATING TNFα-RELATED DISORDERS
WO2007096151A2 (en) 2006-02-23 2007-08-30 Novartis Ag Inhibitors of p38-kinase for treatment of pulmonary hypertension
US20150031736A1 (en) 2012-03-20 2015-01-29 Novartis Ag Use of a pyrazole derivative in the treatment of acute exacerbations of chronic obstructive pulmonary disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
GB0409703D0 (en) 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
US20050277602A1 (en) 2004-05-21 2005-12-15 Grunstein Michael M Methods employing agonists of P38 map kinase for the treatment of asthma
CA2640665A1 (en) 2006-02-10 2007-08-16 Pfizer Products Inc. Pyridinone pyrazole urea and pyrimidinone pyrazole urea derivatives
KR102762199B1 (ko) * 2016-03-08 2025-02-07 메레오 바이오파마 1 리미티드 만성 폐쇄성 폐 질환의 급성 악화 치료를 위한 투약법
BR112018067784A2 (pt) * 2016-03-08 2019-01-15 Mereo Biopharma 1 Ltd regime de dosagem para o tratamento de exacerbações agudas de condições inflamatórias

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030192533A1 (en) 1997-12-31 2003-10-16 Astra Aktiebolag, A Sweden Corporation New method
WO2005009973A1 (en) 2003-06-26 2005-02-03 Novartis Ag 5-membered heterocycle-based p38 kinase inhibitors
WO2005110452A2 (en) 2004-04-09 2005-11-24 Abbott Biotechnology Ltd. MULTIPLE-VARIABLE DOSE REGIMEN FOR TREATING TNFα-RELATED DISORDERS
WO2007096151A2 (en) 2006-02-23 2007-08-30 Novartis Ag Inhibitors of p38-kinase for treatment of pulmonary hypertension
US20150031736A1 (en) 2012-03-20 2015-01-29 Novartis Ag Use of a pyrazole derivative in the treatment of acute exacerbations of chronic obstructive pulmonary disease

Also Published As

Publication number Publication date
JP6741774B2 (ja) 2020-08-19
AU2016397047B2 (en) 2022-04-07
CA3016488A1 (en) 2017-09-14
MX2018010782A (es) 2019-01-10
KR20240101698A (ko) 2024-07-02
US10603306B2 (en) 2020-03-31
US20200281896A1 (en) 2020-09-10
AU2016397047A1 (en) 2018-09-06
BR112018067454A2 (pt) 2019-01-15
JP2019507786A (ja) 2019-03-22
US20190060279A1 (en) 2019-02-28
RU2713203C1 (ru) 2020-02-04
CA3016488C (en) 2023-04-11
MX385717B (es) 2025-03-18
US11129810B2 (en) 2021-09-28
KR20180118667A (ko) 2018-10-31
WO2017153702A1 (en) 2017-09-14

Similar Documents

Publication Publication Date Title
US11129810B2 (en) Dosage regimen for the treatment of acute exacerbations of chronic obstructive pulmonary disease
US10617674B2 (en) Dosage regimen for the treatment of acute exacerbations of inflammatory conditions
JP7372680B2 (ja) 慢性閉塞性肺疾患の急性増悪の予防または減少における３－［５－アミノ－４－（３－シアノベンゾイル）－ピラゾール－１－イル］－ｎ－シクロプロピル－４－メチルベンズアミドの使用
KR102899004B1 (ko) 만성 폐쇄성 폐 질환의 급성 악화의 치료에서의 3-[5-아미노-4-(3-시아노벤조일)-피라졸-1-일]-n-시클로프로필-4-메틸벤즈아미드의 용도
HK40020426B (en) Use of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide in the treatment of acute exacerbations of chronic obstructive pulmonary disease

Legal Events

Date Code Title Description
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20240618

Application number text: 1020187026084

Filing date: 20180907

PA0201 Request for examination
PG1501 Laying open of application
E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20250113

PG1601 Publication of registration